- Fourth quarter revenues were $4.1 million - - Net loss per share was $0.44 for the quarter – - Excluding special items, net loss per share was $0.20 for the quarter* - RALEIGH, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region, today announced its financial results for the fourth quarter ended December 31, 2012.
|Comparison of Selected Financial Results (in millions, except per share data)|
|Three Months Ended December 31,|
|Total revenue||$ 4.1||$ 4.0|
|Net loss per common share||(0.44)||(0.18)|
|Excluding special items*:|
|Net loss per common share||(0.20)||(0.17)|
|* See "Reconciliation of GAAP Financial Information to Non-GAAP Financial Information" below.|